| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 350,736 | 306,681 | ||
| Short-term marketable debt securities | 29,743 | 118,402 | ||
| Other receivables | 4,022 | 3,409 | ||
| Prepaid expenses | 26,714 | 26,989 | ||
| Total current assets | 411,215 | 455,481 | ||
| Operating lease right-of-use assets | 1,911 | 2,251 | ||
| Property and equipment, net | 622 | 667 | ||
| Other non-current assets | 587 | 1,697 | ||
| Total non-current assets | 3,120 | 4,615 | ||
| Total assets | 414,335 | 460,096 | ||
| Trade and other payables | 25,282 | 17,079 | ||
| Accrued expenses and other current liabilities | 21,587 | 8,732 | ||
| Short-term portion of operating lease liabilities | 1,499 | 1,550 | ||
| Total current liabilities | 48,368 | 27,361 | ||
| Long-term debt | 73,741 | 73,381 | ||
| Long-term portion of operating lease liabilities | 486 | 836 | ||
| Pension liability | 549 | 574 | ||
| Total non-current liabilities | 74,776 | 74,791 | ||
| Total liabilities | 123,144 | 102,152 | ||
| Common shares-Common Class A | 6 | 6 | ||
| Common shares-Common Class C | 0 | 0 | ||
| Additional paid-in capital | 689,108 | 683,962 | ||
| Accumulated deficit | -400,486 | -330,757 | ||
| Accumulated other comprehensive income | 278 | 520 | ||
| Total shareholders equity | 288,906 | 353,731 | ||
| Noncontrolling interests | 2,285 | 4,213 | ||
| Total equity | 291,191 | 357,944 | ||
| Total liabilities and equity | 414,335 | 460,096 | ||
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)